News

Protein Discovery and New Objective have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for intact protein analysis using mass spectrometry

Actelion has announced its financial results for the first nine months of 2009, with total net revenues of CHF1,302.5m and operating expenses of CHF939.3m. The company reported an

Almirall has completed a short-term phase II study comparing aclidinium twice daily (BID) vs tiotropium and placebo and has also completed the enrollment of a larger phase III

Dainippon Sumitomo Pharma (DSP) and Sepracor (Sepracor) have announced the successful completion of DSP’s acquisition of Sepracor for $23 per share in cash. DSP completed the acquisition through

XOMA has announced the presentation of peer-reviewed results with XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), at two international conferences. Preclinical results with XOMA 052 in

US Patent and Trademark Office (USPTO) has awarded US Patent No. 7,592,437 to Prometheus Laboratories (Prometheus). The patent, entitled “Genes Involved in Intestinal Inflammatory Diseases and Use Thereof,”

Freeman Technology and Harro Hofliger will present Freeman Technology FT4 Powder Rheometer at the 2009 AAPS Annual Meeting and Exposition Angeles, US. The collaborative work between Freeman Technology

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) have presented results from BLISS-52, the first of two pivotal phase 3 trials of belimumab in seropositive patients with systemic lupus

Ipsen has entered into an agreement under which Ipsen grants exclusive licence rights for Adenuric (febuxostat) to the Menarini Group. Adenuric 80mg and 120mg tablets are indicated for